Ingredient guide · Ingredient reference

What is NMN? Benefits, safety and dosing evidence

NMN is nicotinamide mononucleotide, a precursor involved in making NAD. Human research shows interest in NAD-related markers, but it has not established NMN as a treatment that reverses aging or broadly improves metabolic health. Short-term tolerability findings do not supply a proven long-term daily dose.

Read the evidence ↓

Supplement Science Insights Editorial Team

Published September 23, 2026

A precursor is not an anti-aging outcome

NAD participates in cellular metabolism. Human studies can show changes in NAD or related metabolites without demonstrating longer life, less disability or meaningful improvement in symptoms. Animal findings should remain separate from evidence in people. [1][2]

Recent trials have not shown broad metabolic improvements

A 2026 systematic review included 15 trials and found no significant improvements in several common outcomes, including weight, fasting glucose, HbA1c and lipid profiles. Some vascular signals were preliminary. This summarizes the review rather than independently reanalyzing each study. [3]

Research amounts are not routine recommendations

Included oral exposures ranged from 250 to 2,000 mg daily over 14 days to 24 weeks. Those ranges do not define an optimal personal dose or prove safety over years. Short trials cannot reliably exclude rare adverse effects or establish suitability in every medical condition. [3]

Decide what would count as useful benefit

Imagine a bottle promises cellular youth but provides no clinical outcome relevant to the buyer. Ask what evidence supports the exact preparation and purpose. Do not replace established preventive or medical care with a higher-dose precursor regimen. [4][1]

Hypothetical example — assess a hypothetical NMN claim
Claim or questionEvidence boundary
NAD precursorBiochemical identity
Blood marker increasesNot proven longer life
Study dose rangeNot a prescription
Short tolerabilityNot lifelong safety
What is NMN? Benefits, safety and dosing evidence — original article outline diagram
Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

Sources for this article

  1. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions - PMC
    Source consulted: 2026-09-21. This is a reference resource, not a claim that we conducted the studies or tested a product.
  2. NAD + precursor supplementation in human ageing: clinical evidence and challenges.
    Source consulted: 2026-09-21. This is a reference resource, not a claim that we conducted the studies or tested a product.
  3. Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis - PMC
    Source consulted: 2026-09-21. This is a reference resource, not a claim that we conducted the studies or tested a product.
  4. Dietary Supplements: What You Need to Know - Consumer
    Source consulted: 2026-09-21. This is a reference resource, not a claim that we conducted the studies or tested a product.